RU2019141383A - Способы лечения цервикальной дистонии - Google Patents
Способы лечения цервикальной дистонии Download PDFInfo
- Publication number
- RU2019141383A RU2019141383A RU2019141383A RU2019141383A RU2019141383A RU 2019141383 A RU2019141383 A RU 2019141383A RU 2019141383 A RU2019141383 A RU 2019141383A RU 2019141383 A RU2019141383 A RU 2019141383A RU 2019141383 A RU2019141383 A RU 2019141383A
- Authority
- RU
- Russia
- Prior art keywords
- gly
- botulinum toxin
- positively charged
- composition
- individual
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 47
- 238000011282 treatment Methods 0.000 title claims 31
- 206010044074 Torticollis Diseases 0.000 title claims 12
- 201000002866 cervical dystonia Diseases 0.000 title claims 12
- 108030001720 Bontoxilysin Proteins 0.000 claims 52
- 229940053031 botulinum toxin Drugs 0.000 claims 52
- 239000000203 mixture Substances 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 238000002347 injection Methods 0.000 claims 15
- 239000007924 injection Substances 0.000 claims 15
- 108010039918 Polylysine Proteins 0.000 claims 14
- 229920000656 polylysine Polymers 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 238000011287 therapeutic dose Methods 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 6
- 230000007774 longterm Effects 0.000 claims 5
- 239000007972 injectable composition Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 238000011221 initial treatment Methods 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000002045 lasting effect Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508324P | 2017-05-18 | 2017-05-18 | |
| US62/508,324 | 2017-05-18 | ||
| PCT/US2018/033397 WO2018213710A1 (en) | 2017-05-18 | 2018-05-18 | Methods of treatment for cervical dystonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019141383A true RU2019141383A (ru) | 2021-06-18 |
| RU2019141383A3 RU2019141383A3 (enExample) | 2022-01-19 |
Family
ID=64274745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019141383A RU2019141383A (ru) | 2017-05-18 | 2018-05-18 | Способы лечения цервикальной дистонии |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200179498A1 (enExample) |
| EP (1) | EP3624819A4 (enExample) |
| JP (1) | JP2020520917A (enExample) |
| KR (2) | KR20250037595A (enExample) |
| CN (1) | CN110996979A (enExample) |
| AU (2) | AU2018270092B2 (enExample) |
| BR (1) | BR112019024082A2 (enExample) |
| CA (1) | CA3064070A1 (enExample) |
| CO (1) | CO2019014212A2 (enExample) |
| MX (1) | MX2019013716A (enExample) |
| PH (1) | PH12019502578A1 (enExample) |
| RU (1) | RU2019141383A (enExample) |
| WO (1) | WO2018213710A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181869T1 (hr) * | 2009-10-21 | 2019-01-11 | Revance Therapeutics, Inc. | Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina |
| EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| WO2022081736A1 (en) * | 2020-10-13 | 2022-04-21 | Revance Therapeutics, Inc. | Methods for treating cervical dystonia |
| CA3209156A1 (en) * | 2021-02-21 | 2022-08-25 | Revance Therapeutics, Inc. | Methods of and compositions for treatment of upper limb spasticity |
| WO2025059665A1 (en) | 2023-09-15 | 2025-03-20 | Revance Therapeutics, Inc. | Serial treatment with botulinum toxin for cervical dystonia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557256B2 (en) * | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| PT2985039T (pt) * | 2004-03-03 | 2018-11-09 | Revance Therapeutics Inc | Aplicação tópica e administração transdérmica de toxinas botulínicas |
| HUE037595T2 (hu) * | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| MX366344B (es) * | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
| US8147848B2 (en) * | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
| ES2641068T3 (es) * | 2011-01-07 | 2017-11-07 | Revance Therapeutics, Inc. | Composición tópica que comprende una toxina botulínica y un colorante |
| AU2012283968B2 (en) * | 2011-07-20 | 2016-04-14 | Allergan, Inc. | Botulinum toxins for use in a method for treatment of adipose deposits |
| SG10202004337WA (en) | 2015-10-29 | 2020-06-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| AU2018359962A1 (en) * | 2017-11-03 | 2020-05-28 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect |
| WO2019113133A1 (en) * | 2017-12-04 | 2019-06-13 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
| RU2741221C1 (ru) | 2020-04-30 | 2021-01-22 | Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") | Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом |
-
2018
- 2018-05-18 MX MX2019013716A patent/MX2019013716A/es unknown
- 2018-05-18 CN CN201880042201.4A patent/CN110996979A/zh active Pending
- 2018-05-18 KR KR1020257007090A patent/KR20250037595A/ko active Pending
- 2018-05-18 US US16/614,773 patent/US20200179498A1/en not_active Abandoned
- 2018-05-18 AU AU2018270092A patent/AU2018270092B2/en active Active
- 2018-05-18 RU RU2019141383A patent/RU2019141383A/ru unknown
- 2018-05-18 CA CA3064070A patent/CA3064070A1/en active Pending
- 2018-05-18 JP JP2019563463A patent/JP2020520917A/ja active Pending
- 2018-05-18 BR BR112019024082-9A patent/BR112019024082A2/pt unknown
- 2018-05-18 EP EP18802488.9A patent/EP3624819A4/en active Pending
- 2018-05-18 KR KR1020197037005A patent/KR102777928B1/ko active Active
- 2018-05-18 WO PCT/US2018/033397 patent/WO2018213710A1/en not_active Ceased
-
2019
- 2019-11-18 PH PH12019502578A patent/PH12019502578A1/en unknown
- 2019-12-16 CO CONC2019/0014212A patent/CO2019014212A2/es unknown
-
2021
- 2021-12-09 US US17/547,211 patent/US12257293B2/en active Active
-
2025
- 2025-03-24 US US19/088,478 patent/US20250319168A1/en active Pending
- 2025-07-16 AU AU2025205532A patent/AU2025205532A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250037595A (ko) | 2025-03-17 |
| PH12019502578A1 (en) | 2020-07-20 |
| RU2019141383A3 (enExample) | 2022-01-19 |
| CN110996979A (zh) | 2020-04-10 |
| EP3624819A4 (en) | 2021-03-24 |
| BR112019024082A2 (pt) | 2020-06-16 |
| US20220096610A1 (en) | 2022-03-31 |
| US12257293B2 (en) | 2025-03-25 |
| US20250319168A1 (en) | 2025-10-16 |
| JP2020520917A (ja) | 2020-07-16 |
| KR20200006587A (ko) | 2020-01-20 |
| KR102777928B1 (ko) | 2025-03-10 |
| AU2025205532A1 (en) | 2025-08-07 |
| MX2019013716A (es) | 2020-10-12 |
| AU2018270092B2 (en) | 2025-04-17 |
| WO2018213710A1 (en) | 2018-11-22 |
| EP3624819A1 (en) | 2020-03-25 |
| CA3064070A1 (en) | 2018-11-22 |
| US20200179498A1 (en) | 2020-06-11 |
| CO2019014212A2 (es) | 2020-01-17 |
| AU2018270092A1 (en) | 2019-12-19 |
| NZ759612A (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019141383A (ru) | Способы лечения цервикальной дистонии | |
| RU2471867C2 (ru) | Гиалуронидаза и способ ее применения | |
| RU2020121540A (ru) | Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта | |
| RU2018118651A (ru) | Композиции и способы терапии, связанной с фекальной микробиотой | |
| JP2019194251A5 (enExample) | ||
| RU2013108248A (ru) | Иммуногенные противовоспалительные композиции | |
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2018531984A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| SI2379104T1 (en) | Injectable botulinum toxin formulations | |
| JP2015517488A5 (enExample) | ||
| RU2018123569A (ru) | Связанные с пептидом морфолиновые антисмысловые олигонуклеотиды для лечения миотонической дистрофии | |
| IL294463A (en) | Methods for treating or preventing eye conditions | |
| RU2014141514A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| RU2022102750A (ru) | Применение ботулинических нейротоксинов в лечении | |
| RU2016137292A (ru) | Схема применения соединения fgf-18 | |
| JP2020520917A5 (enExample) | ||
| GB2597172A (en) | Tissue repair | |
| JP2015502389A5 (enExample) | ||
| HK1216007A1 (zh) | 人体生长激素和白蛋白的融合、制剂及其用途 | |
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста | |
| RU2008125169A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а | |
| NZ742018A (en) | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect | |
| IL278311B2 (en) | Preparations and methods for the treatment of glioblastoma | |
| NZ742018B2 (en) | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |